Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.
10.6065/apem.2017.22.1.15
- Author:
Seungah LEE
1
;
Dong Yun LEE
Author Information
1. Department of Bioengineering, College of Engineering, and BK21 PLUS Future Biopharmaceutical Human Resources Training and Research Team, Hanyang University, Seoul, Korea. dongyunlee@hanyang.ac.kr
- Publication Type:Review
- Keywords:
Type 2 diabetes;
Glucagon-like peptide-1;
Glucagon-like peptide-1 receptor;
GLP-1R agonist;
GLP-1R agonist clinical trials
- MeSH:
Diabetes Complications;
Glucagon-Like Peptide 1*;
Glucagon-Like Peptide-1 Receptor*;
Half-Life;
Humans;
Hypoglycemia;
Insulin;
Prevalence
- From:Annals of Pediatric Endocrinology & Metabolism
2017;22(1):15-26
- CountryRepublic of Korea
- Language:English
-
Abstract:
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from various diabetes-related complications. Since there are many patients with T2D that cannot be controlled by previously developed drugs, it has been necessary to develop new drugs, one of which is a glucagon-like peptide-1 (GLP-1) based therapy. GLP-1 has been shown to ameliorate diabetes-related conditions by augmenting pancreatic β-cell insulin secretion and having the low risk of causing hypoglycemia. Because of a very short half-life of GLP-1, many researches have been focused on the development of GLP-1 receptor (GLP-1R) agonists with long half-lives such as exenatide and dulaglutide. Now GLP-1R agonists have a variety of dosing-cycle forms to meet the needs of various patients. In this article, we review the physiological features of GLP-1, the effects of GLP-1 on T2D, the features of several GLP-1R agonists, and the therapeutic effect on T2D.
